UY33110A - Moduladores de CRTH2 - Google Patents

Moduladores de CRTH2

Info

Publication number
UY33110A
UY33110A UY33110A UY33110A UY33110A UY 33110 A UY33110 A UY 33110A UY 33110 A UY33110 A UY 33110A UY 33110 A UY33110 A UY 33110A UY 33110 A UY33110 A UY 33110A
Authority
UY
Uruguay
Prior art keywords
crth2 modulators
crth2
modulators
Prior art date
Application number
UY33110A
Other languages
English (en)
Inventor
Norman Fox
Original Assignee
Ironwood Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43735997&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UY33110(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ironwood Pharmaceuticals Inc filed Critical Ironwood Pharmaceuticals Inc
Publication of UY33110A publication Critical patent/UY33110A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/02Nasal agents, e.g. decongestants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/14Antitussive agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/14Decongestants or antiallergics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/14Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D207/00Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/32Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D207/325Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms with substituted hydrocarbon radicals directly attached to the ring nitrogen atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Reproductive Health (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Otolaryngology (AREA)
  • Oncology (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Transplantation (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
UY33110A 2009-12-23 2010-12-16 Moduladores de CRTH2 UY33110A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US28984109P 2009-12-23 2009-12-23

Publications (1)

Publication Number Publication Date
UY33110A true UY33110A (es) 2011-07-29

Family

ID=43735997

Family Applications (1)

Application Number Title Priority Date Filing Date
UY33110A UY33110A (es) 2009-12-23 2010-12-16 Moduladores de CRTH2

Country Status (21)

Country Link
US (1) US8674115B2 (es)
EP (1) EP2516416A1 (es)
JP (1) JP5731538B2 (es)
KR (1) KR20120098908A (es)
CN (1) CN102822163B (es)
AR (1) AR079492A1 (es)
AU (1) AU2010333829A1 (es)
BR (1) BR112012017756A2 (es)
CA (1) CA2785191A1 (es)
CL (1) CL2012001712A1 (es)
CO (1) CO6640201A2 (es)
CR (1) CR20120343A (es)
EA (1) EA201200855A1 (es)
EC (1) ECSP12011996A (es)
MX (1) MX2012007239A (es)
PH (1) PH12012501280A1 (es)
SG (1) SG181900A1 (es)
TW (1) TW201130810A (es)
UY (1) UY33110A (es)
WO (1) WO2011079007A1 (es)
ZA (1) ZA201204527B (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140187795A1 (en) * 2010-12-08 2014-07-03 Ironwood Pharmaceuticals, Inc. Crth2 modulators and preparation thereof
WO2012130633A1 (en) * 2011-03-25 2012-10-04 Boehringer Ingelheim International Gmbh Pyrazole compounds as crth2 antagonists
WO2013155422A1 (en) 2012-04-12 2013-10-17 Ironwood Pharmaceuticals, Inc. Methods of treating alopecia and acne
JPWO2017104728A1 (ja) * 2015-12-16 2018-11-29 幸久 村田 食物アレルギー治療薬
PT3445767T (pt) 2016-04-22 2020-05-13 Astrazeneca Ab Inibidores de mcl-1 macrocíclicos para o tratamento de cancro
CN115397813A (zh) * 2020-04-16 2022-11-25 豪夫迈·罗氏有限公司 联苯衍生物

Family Cites Families (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US3995631A (en) 1971-01-13 1976-12-07 Alza Corporation Osmotic dispenser with means for dispensing active agent responsive to osmotic gradient
US4203440A (en) 1978-10-23 1980-05-20 Alza Corporation Device having variable volume chamber for dispensing useful agent
US4627850A (en) 1983-11-02 1986-12-09 Alza Corporation Osmotic capsule
EP0192963B1 (de) 1985-02-27 1988-07-20 Werkzeugmaschinenfabrik Oerlikon-Bührle AG Schwingungsmesseinrichtung für ein Spiralkegelradgetriebe auf einer Zahnradprüfmaschine
IL92966A (en) 1989-01-12 1995-07-31 Pfizer Dispensing devices powered by hydrogel
US5304121A (en) 1990-12-28 1994-04-19 Boston Scientific Corporation Drug delivery system making use of a hydrogel polymer coating
US5324280A (en) 1990-04-02 1994-06-28 Alza Corporation Osmotic dosage system for delivering a formulation comprising liquid carrier and drug
US5565473A (en) 1990-10-12 1996-10-15 Merck Frosst Canada, Inc. Unsaturated hydroxyalkylquinoline acids as leukotriene antagonists
US5145684A (en) 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
CN1071924A (zh) * 1991-10-29 1993-05-12 纳幕尔杜邦公司 除草的三唑羧酸酰胺
US5886026A (en) 1993-07-19 1999-03-23 Angiotech Pharmaceuticals Inc. Anti-angiogenic compositions and methods of use
US6099562A (en) 1996-06-13 2000-08-08 Schneider (Usa) Inc. Drug coating with topcoat
EP0837052B1 (en) 1995-06-21 2006-08-23 Shionogi & Co., Ltd. Bicyclic amino derivatives and pgd 2 antagonist containing the same
US5859042A (en) * 1995-09-27 1999-01-12 Ono Pharmaceutical Co., Ltd. Five membered heterocyclic compounds
EP0945450B1 (en) 1996-12-12 2005-05-11 Shionogi & Co., Ltd. Fused heterocyclic benzenecarboxylic acid amide derivatives and pgd2 antagonists containing the same
CZ297324B6 (cs) 1996-12-13 2006-11-15 Shionogi & Co., Ltd. Benzothiofenkarboxamidové deriváty a antagonisty PGD2, které je obsahují
WO2000035419A2 (en) 1998-12-17 2000-06-22 Alza Corporation Conversion of liquid filled gelatin capsules into controlled release systems by multiple coatings
US7217714B1 (en) 1998-12-23 2007-05-15 Agouron Pharmaceuticals, Inc. CCR5 modulators
US6342249B1 (en) 1998-12-23 2002-01-29 Alza Corporation Controlled release liquid active agent formulation dosage forms
DE60115411D1 (de) 2000-04-12 2006-01-05 Merck Frosst Canada & Co Kirkl Verfahren und zusammensetzungen zur behandlung von allergischen zuständen mit pgd2 rezeptor antagonisten
US20010051624A1 (en) 2000-04-12 2001-12-13 Jones Thomas R. Method and compositions for the treatment of allergic conditions using PGD2 receptor antagonists
US6878522B2 (en) 2000-07-07 2005-04-12 Baiyong Li Methods for the identification of compounds useful for the treatment of disease states mediated by prostaglandin D2
CA2440803A1 (en) 2001-03-07 2002-09-12 Pfizer Products Inc. Modulators of chemokine receptor activity
EP1424325A4 (en) 2001-09-07 2005-12-21 Ono Pharmaceutical Co INDOLE DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF AND MEDICAMENTS CONTAINING THEM AS AN ACTIVE AGENT
KR20040044856A (ko) 2001-09-07 2004-05-31 오노 야꾸힝 고교 가부시키가이샤 인돌 유도체 화합물
CA2463272C (en) 2001-10-22 2009-11-17 Laura Cook Blumberg Piperazine derivatives with ccr1 receptor antagonist activity
SE0200411D0 (sv) 2002-02-05 2002-02-05 Astrazeneca Ab Novel use
SE0200356D0 (sv) 2002-02-05 2002-02-05 Astrazeneca Ab Novel use
EP1492789B1 (en) 2002-04-08 2006-06-07 Pfizer Limited Tropane derivatives as ccr5 modulators
EP2423190A1 (en) 2002-05-16 2012-02-29 Shionogi&Co., Ltd. Compounds Exhibiting PGD 2 Receptor Antagonism
AU2003231513A1 (en) 2002-05-16 2003-12-02 Shionogi And Co., Ltd. Pgd2 receptor antagonist
TW200307542A (en) 2002-05-30 2003-12-16 Astrazeneca Ab Novel compounds
SE0201635D0 (sv) 2002-05-30 2002-05-30 Astrazeneca Ab Novel compounds
SE0202241D0 (sv) 2002-07-17 2002-07-17 Astrazeneca Ab Novel Compounds
GB0217431D0 (en) 2002-07-27 2002-09-04 Astrazeneca Ab Novel compounds
OA12894A (en) 2002-08-12 2006-10-13 Pfizer Prod Inc Crystal forms of quinoxaline-2-carboxylic acid [4-carbamoy 1-1-(3-fluorobenzyl)-2,7-dihydroxy-7-met hyl-octyl]-amide.
SE0202483D0 (sv) 2002-08-21 2002-08-21 Astrazeneca Ab Chemical compounds
US7482355B2 (en) 2002-08-24 2009-01-27 Astrazeneca Ab Pyrimidine derivatives as modulators of chemokine receptor activity
GB0221829D0 (en) 2002-09-20 2002-10-30 Astrazeneca Ab Novel compound
GB0221828D0 (en) 2002-09-20 2002-10-30 Astrazeneca Ab Novel compound
AU2003277285B2 (en) 2002-10-04 2007-12-13 Millennium Pharmaceuticals, Inc. PGD2 receptor antagonists for the treatment of inflammatory diseases
US20040092529A1 (en) 2002-10-30 2004-05-13 Pfizer Inc Methods of using piperazine derivatives
US20040097554A1 (en) 2002-10-30 2004-05-20 Pfizer Inc Heteroaryl-hexanoic acid amide derivatives as immonomodulatory agents
US20040116441A1 (en) 2002-10-30 2004-06-17 Pfizer Inc Methods of using sulfonic acid derivatives
SE0203828D0 (sv) 2002-12-20 2002-12-20 Astrazeneca Ab Chemical compounds
ZA200505523B (en) * 2002-12-20 2006-09-27 Amgen Inc Asthma and allergic inflammation modulators
SE0203820D0 (sv) 2002-12-20 2002-12-20 Astrazeneca Ab chemical compounds
AR042628A1 (es) 2002-12-20 2005-06-29 Astrazeneca Ab Derivados de piperidina como moduladores del receptor ccr5
EP1653926A1 (en) 2003-08-04 2006-05-10 Pfizer Products Inc. Dosage forms providing controlled release of cholesteryl ester transfer protein inhibitors and immediate release of hmg-coa reductase inhibitors
BRPI0511676A (pt) * 2004-05-29 2008-01-08 7Tm Pharma As uso medicinal de ligandos receptores
US20080119456A1 (en) 2004-05-29 2008-05-22 Trond Ulven Substituted Thiazoleacetic Acid as Crth2 Ligands
UA85512C2 (ru) 2004-05-29 2009-01-26 7Тм Фарма А/С Лиганды рецептора crth2 для применения в медицине
US20090105218A1 (en) * 2004-05-29 2009-04-23 7Tm Pharma A/S CRTH2 Receptor Ligands For Therapeutic Use
GB0427381D0 (en) 2004-12-14 2005-01-19 Novartis Ag Organic compounds
US7999119B2 (en) * 2006-07-22 2011-08-16 Oxagen Limited Compounds having CRTH2 antagonist activity
JP2011509991A (ja) * 2008-01-22 2011-03-31 オキサジェン リミテッド Crth2アンタゴニスト活性を有する化合物
EP2268281A4 (en) * 2008-02-15 2012-05-02 Abbott Lab THIENOPYRROLES AND PYRROLOTHIAZOLES AS NEW THERAPEUTIC AGENTS

Also Published As

Publication number Publication date
EA201200855A1 (ru) 2013-04-30
BR112012017756A2 (pt) 2016-04-19
SG181900A1 (en) 2012-08-30
CL2012001712A1 (es) 2012-12-07
US8674115B2 (en) 2014-03-18
CA2785191A1 (en) 2011-06-30
KR20120098908A (ko) 2012-09-05
AU2010333829A1 (en) 2012-07-12
EP2516416A1 (en) 2012-10-31
US20110150834A1 (en) 2011-06-23
JP5731538B2 (ja) 2015-06-10
WO2011079007A1 (en) 2011-06-30
JP2013515726A (ja) 2013-05-09
CN102822163B (zh) 2016-01-20
ZA201204527B (en) 2013-09-25
CR20120343A (es) 2013-01-25
AR079492A1 (es) 2012-02-01
PH12012501280A1 (en) 2013-02-04
ECSP12011996A (es) 2012-10-30
CO6640201A2 (es) 2013-03-22
MX2012007239A (es) 2012-10-15
CN102822163A (zh) 2012-12-12
TW201130810A (en) 2011-09-16

Similar Documents

Publication Publication Date Title
BR112012010640A2 (pt) novos moduladores de quinase
PT2414891T (pt) Dispositivos electrocrómicos
BRPI1007450A2 (pt) dispositivo de exibição
BRPI1013318A2 (pt) dispositivo de exibição
BRPI1014636A2 (pt) moduladores de gpr 119
BRPI0924840A2 (pt) dispositivo de exibição
DK2512451T3 (da) Modulator
BRPI1008827A2 (pt) deisobutenizador
BRPI1014968A2 (pt) subalargador
DE112010002728A5 (de) Turboinhalator
DK2435410T3 (da) LXR-modulatorer
EP2490796C0 (en) AGITATION DEVICE
DE112009005323A5 (de) Hebelarmprüfmaschine
DE112009005462T8 (de) Lenkungsssteuervorrichtung
BR112012004964A2 (pt) girocóptero
BRPI1008070A2 (pt) tricianoboratos
BR112012000040A2 (pt) dispositivo de exibição
FR2947857B1 (fr) Agencement de deshuileur
BR112013011865A2 (pt) moduladores de gpr119
BR112012005432A2 (pt) dispositivo de exibição
EP2477076A4 (en) FIXING DEVICE
BRPI1010159A2 (pt) bistuti
UY33110A (es) Moduladores de CRTH2
BRPI1011789A2 (pt) dispositivo de exibição
BR112012003630A2 (pt) dispositivo de exibição

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20181127